Concerns about the design, analyses, and findings of the trial of dopamine serotonin stabilizer RP5063 by Cantillon and colleagues
I would like to comment on the recent clinical trial of dopamine serotonin stabilizer RP5063 by Cantillon and colleagues (Cantillon et al., 2017). First, although the description of rater training is not mandatory and its absence does not negate the findings of the study, it may be especially important to know how raters were trained for this trial because it was conducted across 22 sites in 5 countries, including sites with different languages and cultures. The author of the Positive and Negative Syndrome Scale (PANSS) recommended standardized training of raters so that the disparity in scoring among raters does not exceed plus or minus 1 on the seven-point scale and stressed that training should be identical across persons and across research sites (Kay, 1991).
Source: Schizophrenia Research - Category: Psychiatry Authors: Ahmed Aboraya Tags: Letter to the Editor Source Type: research